BMS and Alder's IL-6 blocker positive in Phase II RA study
This article was originally published in Scrip
Bristol-Myers Squibb and Alder Biopharmaceuticals' monoclonal antibody against interleukin-6 (IL-6), BMS-945429 (also known as ALD518), has met the primary endpoint of a Phase IIa study in rheumatoid arthritis, the companies have said.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.